Biognosys AG, a Swiss Proteomics Company, announced today the launch of its PlasmaDeepDive MRM Panel that enables quantification of 100 human plasma proteins in a single LC-MRM measurement. PlasmaDeepDive is specifically designed for monitoring protein levels in depleted plasma or serum and sets a new standard for clinical research, biomarker screening and development of companion diagnostics.
PlasmaDeepDive MRM Panel includes reagent kit for sample processing after depletion, reference peptide mix and Biognosys’ proprietary software SpectroDive for automated MS method set-up, signal processing and analysis. Thereby, PlasmaDeepDive provides a plug-and-play solution for industrial and academic labs with or without experience in multiplexed protein quantification.
PlasmaDeepDive MRM Panel combines 100 peptide MRM assays in one scheduled MRM method. It includes 16 peptides corresponding to the typically depleted proteins to monitor the depletion quality, 9 housekeeping proteins for normalization and consequently higher reproducibility of the results, and 75 proteins that represent relevant targets for biomarker screening. The panel is independent from the depletion method and requires as little as 50 μg of protein from depleted plasma or serum sample. Due to the use of stable isotope peptide standards for all 100 proteins it delivers highest possible quantitative precision and reproducibility.
As the other Biognosys MRM Panels, PlasmaDeepDive is based on scheduled Multiple Reaction Monitoring (MRM) approach and a unique iRT concept developed at Biognosys. iRT is an empirically derived dimensionless peptide-specific value determined relatively to a standard set of iRT reference peptides which allows extremely precise prediction of peptide retention time on any chromatographic system.
The PlasmaDeepDive MRM Panel is available as a service for measurements at Biognosys’ facility or as a standardized off-the-shelf kit for 96 samples and is perfect for experiments where large sample throughput is required.
About Biognosys
Biognosys is the leading proteomics company offering services and products for highly multiplexed protein quantification. Founded in 2008 as spin-off from the lab of proteomics pioneer Prof. Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transform life science with its cutting edge technological solutions in proteomics measurements.
Please login or sign up to comment.
Commenting guidelines